{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:11:44Z","timestamp":1787929904153,"version":"build-2784847793"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014565","name":"Bausch Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40123-025-01190-3","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T10:20:43Z","timestamp":1752142843000},"page":"2109-2124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Experience with Lifitegrast Ophthalmic Solution in Patients with Dry Eye Disease: A Provider Survey in the USA and Canada"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6718-7418","authenticated-orcid":false,"given":"Cecelia","family":"Koetting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Schweitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2937-1457","authenticated-orcid":false,"given":"Kelly K.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9882-7249","authenticated-orcid":false,"given":"Christopher E.","family":"Starr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mile","family":"Brujic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Racine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis S.","family":"Mah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Farid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Donnenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1608-3563","authenticated-orcid":false,"given":"Carolina","family":"Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Ratay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Cavet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Fain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Feulner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"3","key":"1190_CR1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, et\u00a0al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276\u201383.","journal-title":"Ocul Surf"},{"issue":"3","key":"1190_CR2","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s40123-023-00669-1","volume":"12","author":"JD Sheppard","year":"2023","unstructured":"Sheppard JD, Nichols KK. Dry eye disease associated with meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape. Ophthalmol Ther. 2023;12(3):1397\u2013418.","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"1190_CR3","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","volume":"15","author":"AJ Bron","year":"2017","unstructured":"Bron AJ, de Paiva CS, Chauhan SK, et\u00a0al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438\u2013510.","journal-title":"Ocul Surf"},{"issue":"3","key":"1190_CR4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jtos.2017.05.004","volume":"15","author":"JAP Gomes","year":"2017","unstructured":"Gomes JAP, Azar DT, Baudouin C, et\u00a0al. TFOS DEWS II iatrogenic report. Ocul Surf. 2017;15(3):511\u201338.","journal-title":"Ocul Surf"},{"key":"1190_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jtos.2023.04.004","volume":"28","author":"JS Wolffsohn","year":"2023","unstructured":"Wolffsohn JS, Lingham G, Downie LE, et\u00a0al. TFOS Lifestyle: impact of the digital environment on the ocular surface. Ocul Surf. 2023;28:213\u201352.","journal-title":"Ocul Surf"},{"key":"1190_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ajo.2020.03.044","volume":"216","author":"R Dana","year":"2020","unstructured":"Dana R, Meunier J, Markowitz JT, Joseph C, Siffel C. Patient-reported burden of dry eye disease in the United States: results of an online cross-sectional survey. Am J Ophthalmol. 2020;216:7\u201317.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1190_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067007","volume":"13","author":"KG Boboridis","year":"2023","unstructured":"Boboridis KG, Messmer EM, Ben\u00edtez-Del-Castillo J, et\u00a0al. Patient-reported burden and overall impact of dry eye disease across eight European countries: a cross-sectional web-based survey. BMJ Open. 2023;13(3): e067007.","journal-title":"BMJ Open"},{"issue":"4","key":"1190_CR8","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1016\/j.ophtha.2023.12.041","volume":"131","author":"G Amescua","year":"2024","unstructured":"Amescua G, Ahmad S, Cheung AY, et\u00a0al. Dry eye syndrome preferred practice pattern\u00ae. Ophthalmology. 2024;131(4):P1\u201349.","journal-title":"Ophthalmology"},{"key":"1190_CR9","unstructured":"Xiidra (lifitegrast ophthalmic solution), for topical ophthalmic use. Package insert. Bausch & Lomb, Incorporated; 2023."},{"issue":"6","key":"1190_CR10","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ajo.2011.11.003","volume":"153","author":"CP Semba","year":"2012","unstructured":"Semba CP, Torkildsen GL, Lonsdale JD, et\u00a0al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol. 2012;153(6):1050-60 e1.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1190_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","volume":"121","author":"JD Sheppard","year":"2014","unstructured":"Sheppard JD, Torkildsen GL, Lonsdale JD, et\u00a0al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121(2):475\u201383.","journal-title":"Ophthalmology"},{"issue":"12","key":"1190_CR12","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","volume":"122","author":"J Tauber","year":"2015","unstructured":"Tauber J, Karpecki P, Latkany R, et\u00a0al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. Ophthalmology. 2015;122(12):2423\u201331.","journal-title":"Ophthalmology"},{"issue":"6","key":"1190_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/ICO.0000000000000803","volume":"35","author":"ED Donnenfeld","year":"2016","unstructured":"Donnenfeld ED, Karpecki PM, Majmudar PA, et\u00a0al. Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study. Cornea. 2016;35(6):741\u20138.","journal-title":"Cornea"},{"issue":"1","key":"1190_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","volume":"124","author":"EJ Holland","year":"2017","unstructured":"Holland EJ, Luchs J, Karpecki PM, et\u00a0al. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2017;124(1):53\u201360.","journal-title":"Ophthalmology"},{"key":"1190_CR15","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2147\/OPTH.S226168","volume":"13","author":"DE White","year":"2019","unstructured":"White DE, Zhao Y, Ogundele A, et\u00a0al. Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye. Clin Ophthalmol. 2019;13:2285\u201392.","journal-title":"Clin Ophthalmol"},{"key":"1190_CR16","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2147\/OPTH.S237832","volume":"14","author":"DE White","year":"2020","unstructured":"White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A. Physician satisfaction with anti-inflammatory topical medications for the treatment of dry eye disease. Clin Ophthalmol. 2020;14:931\u20138.","journal-title":"Clin Ophthalmol"},{"key":"1190_CR17","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2147\/OPTH.S296510","volume":"15","author":"JA Hovanesian","year":"2021","unstructured":"Hovanesian JA, Nichols KK, Jackson M, et\u00a0al. Real-world experience with lifitegrast ophthalmic solution (Xiidra\u00ae) in the US and Canada: retrospective study of patient characteristics, treatment patterns, and clinical effectiveness in 600 patients with dry eye disease. Clin Ophthalmol. 2021;15:1041\u201354.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"1190_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12886-023-03174-y","volume":"23","author":"P Karpecki","year":"2023","unstructured":"Karpecki P, Barghout V, Schenkel B, et\u00a0al. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis. BMC Ophthalmol. 2023;23(1):443.","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"1190_CR19","first-page":"269","volume":"263","author":"S Patil","year":"2025","unstructured":"Patil S, Sawale G, Ghuge S, Sathaye S. Quintessence of currently approved and upcoming treatments for dry eye disease. Graefes Arch Clin Exp Ophthalmol. 2025;263(2):269\u201378.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"1190_CR20","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40265-024-02031-6","volume":"84","author":"D Valdes-Arias","year":"2024","unstructured":"Valdes-Arias D, Locatelli EVT, Sepulveda-Beltran PA, Mangwani-Mordani S, Navia JC, Galor A. Recent United States developments in the pharmacological treatment of dry eye disease. Drugs. 2024;84(5):549\u201363.","journal-title":"Drugs"},{"key":"1190_CR21","first-page":"1436","volume":"31","author":"JG Walt","year":"1997","unstructured":"Walt JG, Rowe MM, Stern KL. Evaluating the quality of life impact of dry eye: the Ocular Surface Disease Index. Drug Inf J. 1997;31:1436.","journal-title":"Drug Inf J"},{"issue":"5","key":"1190_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archopht.118.5.615","volume":"118","author":"RM Schiffman","year":"2000","unstructured":"Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118(5):615\u201321.","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"1190_CR23","doi-asserted-by":"publisher","first-page":"820","DOI":"10.18240\/ijo.2022.05.20","volume":"15","author":"SK Rao","year":"2022","unstructured":"Rao SK, Mohan R, Gokhale N, Matalia H, Mehta P. Inflammation and dry eye disease-where are we? Int J Ophthalmol. 2022;15(5):820\u20137.","journal-title":"Int J Ophthalmol"},{"issue":"6283","key":"1190_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/346425a0","volume":"346","author":"TA Springer","year":"1990","unstructured":"Springer TA. Adhesion receptors of the immune system. Nature. 1990;346(6283):425\u201334.","journal-title":"Nature"},{"issue":"10","key":"1190_CR25","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/S0161-6420(00)00347-X","volume":"107","author":"PJ Pisella","year":"2000","unstructured":"Pisella PJ, Brignole F, Debbasch C, et\u00a0al. Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca. Ophthalmology. 2000;107(10):1841\u20139.","journal-title":"Ophthalmology"},{"key":"1190_CR26","first-page":"251584141987036","volume":"11","author":"SL Haber","year":"2019","unstructured":"Haber SL, Benson V, Buckway CJ, Gonzales JM, Romanet D, Scholes B. Lifitegrast: a novel drug for patients with dry eye disease. Ther Adv Ophthalmol. 2019;11:2515841419870366.","journal-title":"Ther Adv Ophthalmol"},{"issue":"4","key":"1190_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.exer.2003.10.024","volume":"78","author":"J Gao","year":"2004","unstructured":"Gao J, Morgan G, Tieu D, et\u00a0al. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sj\u00f6grens syndrome-like MRL\/lpr mice. Exp Eye Res. 2004;78(4):823\u201335.","journal-title":"Exp Eye Res"},{"issue":"6","key":"1190_CR28","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1167\/iovs.09-5078","volume":"52","author":"CJ Murphy","year":"2011","unstructured":"Murphy CJ, Bentley E, Miller PE, et\u00a0al. The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs. Invest Ophthalmol Vis Sci. 2011;52(6):3174\u201380.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"1190_CR29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1089\/jop.2018.0047","volume":"34","author":"R Guimaraes de Souza","year":"2018","unstructured":"Guimaraes de Souza R, Yu Z, Stern ME, Pflugfelder SC, de Paiva CS. Suppression of Th1-mediated keratoconjunctivitis sicca by lifitegrast. J Ocul Pharmacol Ther. 2018;34(7):543\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1190_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/OPTH.S126668","volume":"12","author":"IV Lollett","year":"2018","unstructured":"Lollett IV, Galor A. Dry eye syndrome: developments and lifitegrast in perspective. Clin Ophthalmol. 2018;12:125\u201339.","journal-title":"Clin Ophthalmol"},{"issue":"14","key":"1190_CR31","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1080\/14656566.2017.1372748","volume":"18","author":"ED Donnenfeld","year":"2017","unstructured":"Donnenfeld ED, Perry HD, Nattis AS, Rosenberg ED. Lifitegrast for the treatment of dry eye disease in adults. Expert Opin Pharmacother. 2017;18(14):1517\u201324.","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"1190_CR32","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/jamaophthalmol.2021.3943","volume":"139","author":"EJ Holland","year":"2021","unstructured":"Holland EJ, Jackson MA, Donnenfeld E, et\u00a0al. Efficacy of lifitegrast ophthalmic solution, 5.0%, in patients with moderate to severe dry eye disease: a post hoc analysis of 2 randomized clinical trials. JAMA Ophthalmol. 2021;139(11):1200\u20138.","journal-title":"JAMA Ophthalmol."},{"key":"1190_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jtos.2023.04.010","volume":"29","author":"L Jones","year":"2023","unstructured":"Jones L, Efron N, Bandamwar K, et\u00a0al. TFOS lifestyle: impact of contact lenses on the ocular surface. Ocul Surf. 2023;29:175\u2013219.","journal-title":"Ocul Surf"},{"key":"1190_CR34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jtos.2023.04.011","volume":"29","author":"JAP Gomes","year":"2023","unstructured":"Gomes JAP, Azar DT, Baudouin C, et\u00a0al. TFOS Lifestyle: impact of elective medications and procedures on the ocular surface. Ocul Surf. 2023;29:331\u201385.","journal-title":"Ocul Surf"},{"key":"1190_CR35","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.2147\/OPTH.S184776","volume":"12","author":"AL Gonzalez","year":"2018","unstructured":"Gonzalez AL. Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort. Clin Ophthalmol. 2018;12:2079\u201385.","journal-title":"Clin Ophthalmol"},{"key":"1190_CR36","unstructured":"Schulze MM, Guthrie S, Ho B, Woods J, Jones L. Do symptomatic contact lens wearers benefit from using lifitegrast? Presented at Tear Film and Ocular Surface Society (TFOS) 2024 Conference; 30 October to 2 November 2024; Venice, Italy."},{"key":"1190_CR37","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2147\/OPTH.S120159","volume":"11","author":"WB Trattler","year":"2017","unstructured":"Trattler WB, Majmudar PA, Donnenfeld ED, McDonald MB, Stonecipher KG, Goldberg DF. The Prospective Health Assessment of Cataract Patients\u2019 Ocular Surface (PHACO) study: the effect of dry eye. Clin Ophthalmol. 2017;11:1423\u201330.","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"1190_CR38","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jcrs.2018.06.026","volume":"44","author":"PK Gupta","year":"2018","unstructured":"Gupta PK, Drinkwater OJ, VanDusen KW, Brissette AR, Starr CE. Prevalence of ocular surface dysfunction in patients presenting for cataract surgery evaluation. J Cataract Refract Surg. 2018;44(9):1090\u20136.","journal-title":"J Cataract Refract Surg"},{"key":"1190_CR39","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.2147\/OPTH.S264520","volume":"14","author":"J Hovanesian","year":"2020","unstructured":"Hovanesian J, Epitropoulos A, Donnenfeld ED, Holladay JT. The effect of lifitegrast on refractive accuracy and symptoms in dry eye patients undergoing cataract surgery. Clin Ophthalmol. 2020;14:2709\u201316.","journal-title":"Clin Ophthalmol"},{"key":"1190_CR40","doi-asserted-by":"publisher","first-page":"S737","DOI":"10.1016\/j.jval.2020.08.1985","volume":"23","author":"B Sloesen","year":"2020","unstructured":"Sloesen B, Salzger MP, Syntosi A, et\u00a0al. PSS23 Burden of dry eye disease and treatment experience with lifitegrast: a cross-sectional patient survey in US and Canada [abstract]. Value Health. 2020;23:S737.","journal-title":"Value Health"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01190-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01190-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01190-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T04:21:41Z","timestamp":1757218901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01190-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1190"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01190-3","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cecelia Koetting reports serving as a speaker, consultant, research, and\/or advisory for Allergan\/AbbVie, Alcon, Azura, Bausch\u2009+\u2009Lomb, Blinkjoy, Bruder, Dompe, Harrow, Myze, Orasis, PRN, Tarsus, Topcon Healthcare, Trukera Medical, and Viatris. Justin Schweitzer reports serving as a consultant or speaker for Alcon, Allergan\/AbbVie, Bausch\u2009+\u2009Lomb, Bruder, Domp\u00e9, Glaukos, Iveric Bio, LKC Technologies, MediPrint Ophthalmics, Ocuphire Pharma, Reichert Technologies, ScienceBased Health, Sight Sciences, Sun Pharmaceutical Industries, Tarsus Pharmaceuticals, Th\u00e9a, Topcon Healthcare, Trukera Medical, Visus Therapeutics, and Zeiss; and serving as Chief Medical Editor for Modern Optometry. Kelly K. Nichols reports receiving research funding from Aramis Biosciences, Kowa, ScienceBased Health, Sylentis, and TearScience; and serving as a consultant to and receiving honoraria from Allergan\/AbbVie, Alcon, Aldeyra Therapeutics, Azura Ophthalmics, Bausch\u2009+\u2009Lomb, Bruder, Cavalry Biosciences, Domp\u00e9, HanAll Biopharma, Harrow, Novaliq, Novartis, Oyster Point Pharma (now Viatris), Sight Sciences, Sydnexis, Tarsus, TearSolutions, Th\u00e9a, Topcon Healthcare, and Trukera Medical. Marguerite McDonald reports serving as a consultant to AbbVie, Alcon, Bausch\u2009+\u2009Lomb, Brill, Johnson & Johnson, Nordic Pharma, Ocuphire Pharma, Sun Pharma, Tarsus, and Trukera. Christopher E. Starr reports serving as a consultant to Alcon, Aldeyra Therapeutics, Allergan\/AbbVie, Allgenesis, Amgen, Azura, Bausch\u2009+\u2009Lomb, BlephEx, Bruder Healthcare, CSI Dry Eye, Domp\u00e9, \u00c8ssiri, Eye Care International (ECI), Glaukos, Johnson & Johnson Vision, Kala Pharmaceuticals, Lumenis Be, Novaliq, Novartis, Nuvissa, Oculis, Oyster Point Pharma (now Viatris), Quidel, Sight Sciences, Sofia Biologics, Sun Pharmaceutical Industries, Tarsus, Thea Pharma, Trukera Medical, and Vers\u00e9a Health; and having stock options in CSI Dry Eye, Sofia Biologics, and Nuvissa. Clara C. Chan reports serving on advisory boards, speakers bureaus, or as a consultant for AbbVie, Aequus Pharmaceuticals, Aurion Biotech, Bausch\u2009+\u2009Lomb, Johnson & Johnson, Kala Ophthalmics, Labtician Ophthalmics, Novartis, Santen Pharmaceutical, Sun Pharmaceutical Industries, Th\u00e9a Pharma, and Valeo Pharma; and also has received research funding from Claris Bio and CorNeat. Mile Brujic reports serving as a speaker, consultant, researcher, and\/or advisor, and received meeting support from ABB Optical Group, Alcon, Allergan\/AbbVie, Art Optical, Bausch\u2009+\u2009Lomb Health, BlephEx, Contamac, CooperVision, CSEye, Domp\u00e9, Euclid, Eyevance Pharmaceuticals, Horizon Therapeutics, Johnson & Johnson Vision Care, Kala Pharmaceuticals, Luneau, Novartis, Optovue, Oyster Point Pharma, RVL, Sight Sciences, Sun Pharmaceutical Industries, Tangible Science, Tarsus, Viatris, Visionix, Walman Optical, and ZeaVision. Louis Racine reports serving on advisory boards, speakers bureaus, or as a consultant for Allergan, AbbVie, Alcon, Bausch\u2009+\u2009Lomb, Sun Pharmaceutical Industries, Th\u00e9a Pharma, Staar Surgical, and Rayner Group. Francis S. Mah reports receiving grants from Allergan; reports personal fees from Shire\/Takeda\/Novartis; and being a consultant for Allergan, Eyevance Pharmaceuticals, Kala Pharmaceuticals, Novartis, and Sun Pharmaceutical Industries. Melissa Barnett reports serving on advisory boards or as a consultant, global ambassador, or speaker for ABB, AbbVie, Alcon, Azura Ophthalmics, Bausch\u2009+\u2009Lomb, BCLA, Bruder Healthcare, Bruno Vision, Cloudbreak Pharma, CooperVision, Domp\u00e9, Epion, Gas Permeable Lens Institute, Ocusoft, Orasis Pharmaceuticals, Percept, ScienceBased Health, Sj\u00f6gren\u2019s Foundation, STAPLE Program, Tarsus Pharmaceuticals, Th\u00e9a Pharma, and Visus Therapeutics. Marjan Farid reports serving as a consultant for Bausch\u2009+\u2009Lomb and Johnson & Johnson Vision. Eric D. Donnenfeld reports serving as a consultant to Bausch\u2009+\u2009Lomb, Ocular Therapeutix, and Rayner; and reports receiving grants from Omeros. Carolina Mercado reports serving as a consultant to Bausch\u2009+\u2009Lomb. Michelle Ratay, Megan Cavet, Robert Ryan, and Joel Fain are employees of Bausch\u2009+\u2009Lomb. Lisa K. Feulner reports serving on advisory boards or as a consultant, global ambassador, or speaker for AbbVie, Alcon, Bausch\u2009+\u2009Lomb, Bruder Healthcare Company, Carl Zeiss Meditec, Inc., Glaukos, Regener-Eyes, Science Based Health, Sun Ophthalmics, Thea Pharma, and Tarsus Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was determined IRB-exempt by WCG IRB (Princeton, NJ, USA; IRB tracking ID 202425583). The study was exempt from IRB approval under 45 CFR \u00a7 46.104(d)(2) because the research only includes interactions involving survey procedures; and there are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}